TISIDB

Summary
Symbol	MEX3B
Name	mex-3 RNA binding family member B
Aliases	DKFZp434J0617; RNF195; RKHD3; ring finger and KH domain containing 3; mex-3 homolog B (C. elegans); MEX-3B; ......
Chromosomal Location	15q25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Cytoplasm Cytoplasm, P-body Cytoplasmic granule Note=Predominantly expressed in the cytoplasm and shuttles between the cytoplasm and the nucleus through the CRM1 export pathway. Localization to P-bodies is dependent on 14-3-3.
Domain	PF00013 KH domain
Function	RNA-binding protein. May be involved in post-transcriptional regulatory mechanisms.

> Gene Ontology [ TOP ]
Biological Process	GO:0046777 protein autophosphorylation
Molecular Function	-
Cellular Component	GO:0000932 cytoplasmic mRNA processing body GO:0035770 ribonucleoprotein granule GO:0036464 cytoplasmic ribonucleoprotein granule

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	MEX3B
Name	mex-3 RNA binding family member B
Aliases	DKFZp434J0617; RNF195; RKHD3; ring finger and KH domain containing 3; mex-3 homolog B (C. elegans); MEX-3B; ......
Chromosomal Location	15q25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MEX3B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between MEX3B and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
29674509	melanoma	Inhibit immunity (T cell function); immunotherapy target	MEX3B is a post-transcriptional regulator of HLA-A, validating the critical role of tumor-intrinsic antigen presentation in T cell immunotherapy and indicating a new putative molecular target.
29496759	Melanoma	resistant to immunotherapy	The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. In addition, significantly decreased levels of IFNγ were secreted from TILs incubated with MEX3B-overexpressing tumor cells. MEX3B mediates resistance to cancer immunotherapy by binding to the 3' UTR ofHLA-Ato destabilize theHLA-AmRNA and thus downregulate HLA-A expression on the surface of tumor cells, thereby making the tumor cells unable to be recognized and killed by T cells.

Summary
Symbol	MEX3B
Name	mex-3 RNA binding family member B
Aliases	DKFZp434J0617; RNF195; RKHD3; ring finger and KH domain containing 3; mex-3 homolog B (C. elegans); MEX-3B; ......
Chromosomal Location	15q25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MEX3B in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MEX3B
Name	mex-3 RNA binding family member B
Aliases	DKFZp434J0617; RNF195; RKHD3; ring finger and KH domain containing 3; mex-3 homolog B (C. elegans); MEX-3B; ......
Chromosomal Location	15q25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MEX3B in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.876	0.00753
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.878	0.238
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.888	0.234
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.041	0.93
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.166	0.883
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.106	0.947
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.009	0.982
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.179	0.853
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.283	0.775
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.531	0.477
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.491	0.108
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.167	0.33

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MEX3B in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	0	9.1	0.458
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	16.7	0	16.7	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MEX3B
Name	mex-3 RNA binding family member B
Aliases	DKFZp434J0617; RNF195; RKHD3; ring finger and KH domain containing 3; mex-3 homolog B (C. elegans); MEX-3B; ......
Chromosomal Location	15q25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MEX3B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MEX3B
Name	mex-3 RNA binding family member B
Aliases	DKFZp434J0617; RNF195; RKHD3; ring finger and KH domain containing 3; mex-3 homolog B (C. elegans); MEX-3B; ......
Chromosomal Location	15q25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MEX3B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MEX3B. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MEX3B
Name	mex-3 RNA binding family member B
Aliases	DKFZp434J0617; RNF195; RKHD3; ring finger and KH domain containing 3; mex-3 homolog B (C. elegans); MEX-3B; ......
Chromosomal Location	15q25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MEX3B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MEX3B
Name	mex-3 RNA binding family member B
Aliases	DKFZp434J0617; RNF195; RKHD3; ring finger and KH domain containing 3; mex-3 homolog B (C. elegans); MEX-3B; ......
Chromosomal Location	15q25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MEX3B expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MEX3B
Name	mex-3 RNA binding family member B
Aliases	DKFZp434J0617; RNF195; RKHD3; ring finger and KH domain containing 3; mex-3 homolog B (C. elegans); MEX-3B; ......
Chromosomal Location	15q25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MEX3B and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MEX3B
Name	mex-3 RNA binding family member B
Aliases	DKFZp434J0617; RNF195; RKHD3; ring finger and KH domain containing 3; mex-3 homolog B (C. elegans); MEX-3B; ......
Chromosomal Location	15q25.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MEX3B collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MEX3B